Coronavirus Vaccine Market
完整報告名稱與涵蓋範圍
Coronavirus Vaccine Market Size, Share & Trends Analysis Report By Infection Type (HCoV-229E, HCoV-OC43, SARS-CoV, New Haven CoV, HKU1-CoV, and MERS-CoV), Vaccine Type (Inactivated coronavirus vaccine, Live attenuated coronavirus vaccine, S-Protein based coronavirus vaccine), Region, And Segment Forecasts, 2023-2031.
報告摘要
The Coronavirus Vaccine Market is positioned for steady expansion, with a projected CAGR of 12.0% from 2024 to 2034.
Coronavirus Vaccine covers reshaping how healthcare entities approach this space.
The market's upward path is propelled by escalating healthcare spending, technological evolution, and the escalating focus on personalized and precision-based approaches in healthcare.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, propelled by rapid industrialization and expanding end-user bases.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Coronavirus Vaccine Market Snapshot
Chapter 4. Global Coronavirus Vaccine Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Clinical Trial/Pipeline Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Major Investment, Partnerships and Collaborations in COVID 19 Research
Chapter 5. Market Segmentation 1: By Infection Type, Estimates & Trend Analysis
5.1. By Infection Type, & Market Share, 2020 & 2030
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Infection Type:
5.2.1. HCoV-229E
5.2.2. HCoV-OC43
5.2.3. SARS-CoV
5.2.4. New Haven CoV
5.2.5. HKU1-CoV
5.2.6. MERS-CoV
Chapter 6. Market Segmentation 2: By Vaccine Type Estimates & Trend Analysis
6.1. By Vaccine Type & Market Share, 2020 & 2030
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Vaccine Type:
6.2.1. Protein subunit
6.2.2. Viral Vector (non-replicating)
6.2.3. DNA
6.2.4. Inactivated Virus
6.2.5. RNA
6.2.6. Viral Vector (replicating)
6.2.7. Virus Like Particle
6.2.8. Others
Chapter 7. Market Segmentation 3: By End-Users Estimates & Trend Analysis
7.1. By End-Users & Market Share, 2020& 2030
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By End-Users:
7.2.1. Hospitals
7.2.2. Clinics
7.2.3. Research Institutes
7.2.4. Others
Chapter 8. Coronavirus Vaccine Market Segmentation 3: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Coronavirus Vaccine Market revenue (US$ Million) estimates and forecasts By Infection Type, 2020-2030
8.1.2. North America Coronavirus Vaccine Market revenue (US$ Million) estimates and forecasts By Vaccine Type, 2020-2030
8.1.3. North America Coronavirus Vaccine Market revenue (US$ Million) estimates and forecasts By End-Users, 2020-2030
8.1.4. North America Coronavirus Vaccine Market revenue (US$ Million) estimates and forecasts by country, 2020-2030
8.2. Europe
8.2.1. Europe Coronavirus Vaccine Market revenue (US$ Million) By Infection Type, 2020-2030
8.2.2. Europe Coronavirus Vaccine Market revenue (US$ Million) By Vaccine Type, 2020-2030
8.2.3. Europe Coronavirus Vaccine Market revenue (US$ Million) By End-Users, 2020-2030
8.2.4. Europe Coronavirus Vaccine Market revenue (US$ Million) by country, 2020-2030
8.3. Asia Pacific
8.3.1. Asia Pacific Coronavirus Vaccine Market revenue (US$ Million) By Infection Type, 2020-2030
8.3.2. Asia Pacific Coronavirus Vaccine Market revenue (US$ Million) By Vaccine Type, 2020-2030
8.3.3. Asia Pacific Coronavirus Vaccine Market revenue (US$ Million) By End-Users, 2020-2030
8.3.4. Asia Pacific Coronavirus Vaccine Market revenue (US$ Million) by country, 2020-2030
8.4. Latin America
8.4.1. Latin America Coronavirus Vaccine Market revenue (US$ Million) By Infection Type, (US$ Million)
8.4.2. Latin America Coronavirus Vaccine Market revenue (US$ Million) By Vaccine Type, (US$ Million)
8.4.3. Latin America Coronavirus Vaccine Market revenue (US$ Million) By End-Users, (US$ Million)
8.4.4. Latin America Coronavirus Vaccine Market revenue (US$ Million) by country, (US$ Million) 2020-2030
8.5. Middle East & Africa
8.5.1. Middle East & Africa Coronavirus Vaccine Market revenue (US$ Million) By Infection Type, (US$ Million)
8.5.2. Middle East & Africa Coronavirus Vaccine Market revenue (US$ Million) By Vaccine Type, (US$ Million)
8.5.3. Middle East & Africa Coronavirus Vaccine Market revenue (US$ Million) By End-Users, (US$ Million)
8.5.4. Middle East & Africa Coronavirus Vaccine Market revenue (US$ Million) by country, (US$ Million) 2020-2030
Chapter 9. Competitive Landscape
9.1. Company Profiles
9.1.1. I-Mab Biopharma
9.1.2. Medicago
9.1.3. Airway Therapeutics
9.1.4. Tiziana Life Sciences
9.1.5. Inovio Pharmaceuticals
9.1.6. Novavax, Inc
9.1.7. Moderna
9.1.8. AstraZeneca
9.1.9. Pfizer
9.1.10. Johnson &Johnson
9.1.11. GlaxoSmithKline
9.1.12. Bharath Biotech
9.1.13. Serum Institute of India
9.1.14. Sinopharm
9.1.15. AnGes
9.1.16. AIVITABiomedical
9.1.17. CanSinoBio
9.1.18. eubiologics
9.1.19. Genexine
9.1.20. GreenLight Bioscience
9.1.21. Gennova
9.1.22. Heat Biologics
9.1.23. INOVIO
9.1.24. IIBR
9.1.25. medicago
9.1.26. Symvivo
9.1.27. Valneva
9.1.28. Zydus Cadila
9.1.29. CODAGENIX Inc.
9.1.30. Other Prominent Player
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們